Loading...
OTCM
GUBRF
Market cap732mUSD
May 06, Last price  
60.15USD
Name

Gubra A/S

Chart & performance

D1W1MN
OTCM:GUBRF chart
P/E
—
P/S
—
EPS
102.96
Vol. 1Y
—
Shs. 5Y
0.18%
Rev. 5Y
72.57%
Div Yld LY
—
Div Yld TTM
—
Revenues
2.64b
+892.25%
172,301,000255,326,000199,381,000205,005,000265,741,0002,636,811,000
Net income
1.69b
P
12,692,00067,938,0004,310,000-44,524,000-36,498,0001,690,566,000
CFO
1.71b
+34,017.57%
32,987,00088,513,00024,340,000-49,419,0005,019,0001,712,361,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.

Related entities

Subsidiaries (2)
Gubra Alpha ApS
Gubra Beta ApS

Key people

Henrik Blou
Chief Executive Officer · since 2016
Independent Deputy Chairman of the Board · since 2022
Jacob Jelsing
Co-Founder, Director · since 2025
Kristian Borbos
Chief Financial Officer · since 2022
Niels Vrang
Co-Founder, Director · since 2025
Astrid Haug
Independent Board Member
Monika Lessl
Independent Board Member
Claudia Mitchell
Independent Board Member · since 2025
Arndt Schottelius
Independent Board Member · since 2022
IPO date
Apr 04, 2023
Employees
Domiciled in
DK
Incorporated in
DK
Headquarters & legal address
Hørsholm Kongevej 11 B
Hørsholm, 84 2970
DK

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT